Innovating Safer & More Effective T-Cell Engagers in Solid Tumors to Secure Clinical Efficacy & Accelerate Transformative Immunotherapies to Patients
The T-cell engager field is advancing faster than ever. With multiple clinical approvals validating the staying power of this modality, and a new wave of next-generation solid tumor and autoimmune programs moving rapidly towards the clinic, the momentum behind T-Cell engagers has never been stronger. These therapies are increasingly cited as one of the most promising drivers of the next era of immunotherapy.
Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such as BMS x JanuX Therapeutics, Candid Therapeutics x WuXi Biologics and AbbVie x EvolveImmune signal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology and autoimmune disease.
Moving from Boston to San Diego for 2026, the 8th T-Cell Engager Therapeutics Summit stands as the industry’s most comprehensive end-to-end meeting dedicated to advancing, optimizing and translating T-cell engagers.
This case-study driven forum is designed to equip engineering, discovery, R&D, translational and clinical development teams with the actionable insights needed to engineer safer, more potent, durable and precisely targets TCEs for solid tumors, while also spotlighting the breakthroughs extending engager biology into autoimmune and inflammatory diseases.
If accelerating your TCE pipeline is a priority, this is a meeting you cannot afford to miss.
I’m excited to attend this conference due to its highly focused topics in TCE therapy. I appreciate the valuable opportunity to meet experts in the field and discuss novel platforms and clinical applications.
Ran You, Principal Scientist, Amgen
I’m excited to exchange ideas and connect with leaders in the field of T cell engagers. I look forward to discussing key challenges, exploring potential next breakthroughs, and learning about the latest advances in improving molecule design.
Genevieve Desjardins, Principal Scientist, Zymeworks
The T-Cell Engager Summit brings together a highly focused community working to push the therapeutic boundaries of T-cell engagers, particularly in solid tumors. I’m excited to engage with scientists and clinicians tackling similar challenges in target selection, safety, and multi-specific design, and to exchange practical lessons learned across discovery and early clinical development. The meeting is a valuable forum for sharing emerging approaches, pressure-testing ideas, and helping shape where the field goes next.
Alexander Martinko, Senior Director – Antibody Engineering & Design, Cartography Bio
Explore the Full Event Guide
- 120+ Industry Attendees
- 28+ World-Class Speakers
- 8+ Hours of Unrivalled Networking Opportunities
- 6 Deep-Dive Workshops
- 1 Modality at the Front & Center
- The only industry forum dedicated to advancing T-cell engagers to transform the oncology and autoimmune landscapes
Official Partners
Attending Companies Include
Explore Related Events
Explore the Brand-New Agenda
Hear the latest industry breakthroughs in T-Cell Engager development and gain exclusive modality and platform insights during our packed agenda.
Partner With Us
Position yourself as the go-to service provider of the rapidly progressing T-Cell Engager landscape to ensure your brand is at the heart of deals in this evolving space.
Join Biopharma Experts
Be part of the most critical conversations shaping the future of solid tumor and autoimmune therapy, where you can connect with like-minded experts across every stage of drug development.